Table 1 State of SLE patients included in the study
| Â | SLE patients | |
|---|---|---|
| Â | Quiescent disease (n= 33) | Active disease (n= 37) |
No. male/female | 5/28 | 7/30 |
Age (years), median (range) | 45 (19 to 73) | 37 (18 to 73) |
SLEDAI, median (range) | 2 (0 to 4) | 10 (5 to 16) *** |
Anti-dsDNA (E/ml), median (range) | 25 (3 to 408) | 230 (3 to 6,683) *** |
C3(g/l), median (range) | 0.99 (0.54 to 1.46) | 0.73 (0.21 to 1.68) *** |
C4 (g/l), median (range) | 0.15 (0.06 to 0.28) | 0.12 (0.02 to 0.30) * |
CRP (g/I), median (range) | 5 (5 to 27) | 6 (1 to 92) |
No. with/without treatment | 31/2 | 29/8 |
Users of Prednisone (%) Dose (mg/day), median (range) | 19 (58%) 10 (2.5 to 50) | 21 (57%) 7.50 (2.5 to 100) |
Users of Azathioprine (%) Dose (mg/day), median (range) | 8 (24%) 150 (50 to 150) | 5 (14%) 100 (75 to 150) |
Users of Hydroxychloroquine (%) Dose (mg/day), median (range) | 19 (58%) 400 (150 to 600) | 16 (43%) 400 (200 to 1,200) |